Blood test could replace risky amniocentesis for down syndrome diagnosis
NCT ID NCT01725438
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new blood test to diagnose Down syndrome (trisomy 21) in pregnant women without the risks of invasive procedures like amniocentesis. Researchers collected blood samples from 150 pregnant women at high risk and analyzed fetal cells. The goal is to provide a safe, accurate, and cost-effective alternative to current diagnostic methods.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could provide a safe, non-invasive blood test to diagnose Down syndrome during pregnancy, avoiding the miscarriage risk of current invasive tests.
- What could go wrong
- This is a validation study with 150 participants, not yet proven in large populations. The method may not be accurate enough or cost-effective for widespread use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRISOMY 21 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hopital de Béclère
Clamart, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New nasal device could help kids with down syndrome sleep soundly
- New study maps normal heart function in newborns
- Simple blood test could replace risky prenatal procedures for down syndrome
- Father's age may matter in down syndrome screening, study suggests
- Massive biobank aims to unlock secrets of down syndrome